Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

[1]  C. Lemière,et al.  Low blood eosinophil counts are not always a reliable marker of clinical response to mepolizumab in severe asthma. , 2018, The journal of allergy and clinical immunology. In practice.

[2]  H. Ortega,et al.  Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab , 2018, Advances in Therapy.

[3]  H. Ortega,et al.  Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma. , 2018, The journal of allergy and clinical immunology. In practice.

[4]  Oliver N Keene,et al.  Biomarkers for severe eosinophilic asthma , 2017, The Journal of allergy and clinical immunology.

[5]  J. Fahrenholz,et al.  Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. , 2017, The journal of allergy and clinical immunology. In practice.

[6]  F. Albers,et al.  Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. , 2017, The Lancet. Respiratory medicine.

[7]  K. Rothman,et al.  Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma , 2017, The Journal of allergy and clinical immunology.

[8]  J. FitzGerald,et al.  The safety of mepolizumab for the treatment of asthma , 2017, Expert opinion on drug safety.

[9]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[10]  C. Lemière,et al.  Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. , 2016, Chest.

[11]  H. Ortega,et al.  Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. , 2016, Clinical therapeutics.

[12]  M. Thiry,et al.  Lung-resident eosinophils represent a distinct regulatory eosinophil subset. , 2016, The Journal of clinical investigation.

[13]  K. Ohta,et al.  A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan , 2016, International Archives of Allergy and Immunology.

[14]  P. Polgreen,et al.  Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance , 2015, Annals of the rheumatic diseases.

[15]  E. Bleecker,et al.  Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. , 2014, The Lancet. Respiratory medicine.

[16]  W. Busse,et al.  Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. , 2014, The Lancet. Respiratory medicine.

[17]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[18]  I. Pavord,et al.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.

[19]  K. Rothman,et al.  Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. , 2014, The Journal of allergy and clinical immunology.

[20]  I. Pavord,et al.  Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. , 2014, The Journal of allergy and clinical immunology.

[21]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[22]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[23]  S. Wenzel.  Severe asthma: from characteristics to phenotypes to endotypes , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  C. Mackay,et al.  MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. , 2010, The Journal of allergy and clinical immunology.

[25]  William W Busse,et al.  Severe exacerbations and decline in lung function in asthma. , 2009, American journal of respiratory and critical care medicine.

[26]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[27]  D. Postma,et al.  Severe exacerbations predict excess lung function decline in asthma , 2007, European Respiratory Journal.

[28]  L. Boulet,et al.  Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations , 2006, European Respiratory Journal.

[29]  D. Hepner,et al.  Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. , 2006, The Journal of allergy and clinical immunology.

[30]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[31]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[32]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .